Clinical trials: Protozoan Infections
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P.
- Trial name
- NCT00677833
- Testing
- Azithromycin plus Chloroquine, Artemether-lumefantrine
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
Invasive Fungal Infections, Neutropenic Fever
Human Bioequivalence Study of Amphotericin B Liposome for Injection
Single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design to evaluate the human bioequivalence of two Amphotericin B Liposome for Injection formulations
- Conditions
- Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis
- Trial name
- NCT06977490
- Testing
- Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.), Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Trichomonas Vaginalis
Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing
The objective of this study is to obtain female first-catch urine, vaginal swab, endocervical swab, and cervical specimens collected in PreservCyt Solution ("PreservCyt Specimens") for testing with the APTIMA Trichomonas…
- Trial name
- NCT01427023
- Testing
- APTIMA Trichomonas vaginalis (ATV) Assay
- Where
- 7 sites in United States
- Volunteers
- 532 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Paludism
Evaluation of the STANDARD G6PD Rapid Test for Assaying the Enzymatic Activity of G6PD in French Guiana
In French Guiana, malaria is endemic and two species predominate: P. falciparum and P. vivax. The treatments against Plasmodium vivax malaria are: nivaquine for 3 days against circulating blood parasites and primaquine for 14…
- Trial name
- G6PD facile (NCT04698980)
- Testing
- blood samples (venous and capillary at the fingertip)
- Where
- French Guiana
- Volunteers
- 150 people
- Sponsor
- Institut Pasteur
Malaria
Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults
The proposed trial will evaluate whether relatively non immune populations in endemic countries can be effectively infected with aseptic, purified, cryopreserved sporozoites (PfSPZ Challenge) given intradermally.
- Trial name
- NCT01540903
- Testing
- PfSPZ Challenge, Saline
- Where
- Tanzania
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Plasmodium Falciparum
Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults
This is a single center, randomized, placebo-controlled, double-blind trial to assess the safety and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation (DVI).
- Trial name
- NCT02418962
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Equatorial Guinea
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Cryptosporidium Infection, Cryptosporidiosis
Study of Efficacy and Safety of ABO809 in Healthy Participants
The purpose of this Phase I controlled human infection model (CHIM) study was to determine if oral administration of a good manufacturing practice (GMP) supply of Cryptosporidium parvum oocysts (ABO809) to healthy volunteers…
- Trial name
- NCT05036668
- Testing
- Cryptosporidium parvum oocysts (ABO809)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Chagas Disease
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
This study evaluate the efficacy and safety of benznidazole in the treatment of chronic indeterminate Chagas disease in children.
- Trial name
- NCT04024163
- Testing
- Benznidazole
- Where
- 9 sites in Argentina, Bolivia and 1 more
- Volunteers
- 178 people
- Sponsor
- Insud Pharma
Cryptosporidiosis, HIV Infections
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients
PRIMARY: To assess the effect of bovine anti-Cryptosporidium immunoglobulin (BACI) on the volume of diarrhea due to Cryptosporidium parvum in AIDS patients who have protracted Cryptosporidium enteritis.
- Trial name
- NCT00002248
- Testing
- Cryptosporidium Immune Whey Protein Concentrate (Bovine)
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Univax Biologics Inc
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to atovaquone-proguanil for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
- Trial name
- NCT00084227
- Testing
- Azithromycin/Chloroquine, Atovaquone/Proguanil
- Volunteers
- 244 people
- Sponsor
- Pfizer
Malaria
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
The study intends to establish proof of concept for a fractional dose schedule under conditions of natural exposure in children 5-17 months old at first vaccination.
- Trial name
- NCT03276962
- Testing
- RTS,S/AS01E (Full dose), RTS,S/AS01E (1/5th dose), Rabies vaccine
- Where
- 2 sites in Ghana, Kenya
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
This study is designed to characterise P. falciparum transmission intensity in subjects aged ≥6 months and <10 years by measurement of P.
- Trial name
- NCT01954264
- Testing
- Capillary blood sample, Data collection
- Where
- 3 sites in Burkina Faso, Senegal
- Volunteers
- 2,421 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate
The aim of this study is to evaluate the role of clindamycin and artesunate as possible combination partners for fosmidomycin to protect it from its susceptibility to recrudescent infections when used as monotherapy for acute…
- Trial name
- JP015 (NCT01002183)
- Testing
- Fosmidomycin
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Jomaa Pharma GmbH
Malaria
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on D28 of administration of Coarsucam™ (artesunate+amodiaquine fixed-dose combination), as a single daily dose, in…
- Trial name
- NCT00316329
- Testing
- Artesunate + Amodiaquine
- Where
- 5 sites in Cameroon, Madagascar and 2 more
- Volunteers
- 1,032 people
- Sponsor
- Sanofi
Leishmaniasis
Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects
The purpose of this study is to evaluate the safety, tolerability and PK profile of single and repeat ascending doses of GSK3186899 in healthy subjects.
- Trial name
- NCT03874234
- Testing
- GSK3186899
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria
The purpose of this study is to compare the safety and efficacy in children aged 6 - 59 months with uncomplicated malaria, treated with either conventional artemether/lumefantrine tablets(Coartem®) or artemether/ lumefantrine…
- Trial name
- NCT00529867
- Testing
- Artemether/lumefantrine tablets, Artemether/Lumefantrine suspension
- Where
- Kenya
- Volunteers
- 267 people
- Sponsor
- Dafra Pharma
Plasmodium Falciparum Malaria
Superiority of ArTiMist Versus Quinine in Children With Severe Malaria
The purpose of this study is to demonstrate that ArTiMist (sublingual artemether spray) is better than intravenous quinine in reducing parasite counts by >= 90% within 24 hours after the start of treatment in children with severe…
- Trial name
- NCT01258049
- Testing
- Artemether Sublingual Spray, Quinine
- Where
- 3 sites in Burkina Faso, Ghana and 1 more
- Volunteers
- 151 people
- Sponsor
- Proto Pharma Ltd
Trichotillomania
Technology Assisted Treatment of Trichotillomania: Open Trial
This open-label feasibility trial evaluates the use of the Keen2 awareness bracelet for adults with trichotillomania (hair-pulling disorder). Participants will use the bracelet for eight weeks.
- Trial name
- NCT07224126
- Testing
- Keen2 Predictive Awareness Bracelet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HabitAware Inc.
Malaria
Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance
Primary Objective: To demonstrate the non-inferiority, in terms of clinical and parasitological efficacy on Day 14, of administration of Arsucam® as a single daily intake versus two daily intakes.
- Trial name
- ATOL (NCT00445796)
- Testing
- Artesunate, Amodiaquine
- Where
- 2 sites in Cameroon, Senegal
- Volunteers
- 300 people
- Sponsor
- Sanofi
Leishmaniasis; American, Cutaneous, Drug Side Effect
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.
- Trial name
- NCT03084952
- Testing
- 18-Methoxycoronaridine, Glucantime
- Volunteers
- 52 people
- Sponsor
- Infan Industria Quimica Farmaceutica Nacional